Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
暂无分享,去创建一个
[1] J. Cayuela,et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] John M.L. Ebos,et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of respon , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Baruchel,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.
[4] For cancer, seek and destroy or live and let live? , 2009, Nature.
[5] E. López-Aguilar,et al. Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children. , 2008, Archives of medical research.
[6] L. Zitvogel,et al. The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.
[7] Dominique,et al. Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy , 2008, Clinical Cancer Research.
[8] Dushyant V. Sahani,et al. Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.
[9] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[10] Russell G. Jones,et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism , 2009, Nature.
[11] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[12] P. Fidias,et al. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. LoPiccolo,et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[14] Nicolas André,et al. Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.
[15] R. Gatenby. A change of strategy in the war on cancer , 2009, Nature.
[16] M. Sporn,et al. The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.
[17] A. Moosmann,et al. Cox-Inhibitors Relieve the Immunosuppressive Effect of Tumor Cells and Improve Functions of Immune Effectors , 2006, International journal of immunopathology and pharmacology.
[18] N. André,et al. Children Treated With Metronomic Chemotherapy in a Low-income Country: METRO-MALI-01 , 2011, Journal of pediatric hematology/oncology.
[19] G. Vassal. Has chemotherapy reached its limits in pediatric cancers? , 2005, European journal of cancer.
[20] N. André,et al. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. , 2008, Clinical therapeutics.
[21] Gabriele Bergers,et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.
[22] J. Rich,et al. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Radice,et al. Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents , 2010, Oncology.
[24] N. André,et al. Looking at the seemingly contradictory role of vinblastine in anaplastic large-cell lymphoma from a metronomic perspective. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Robert A. Gatenby,et al. Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.
[26] Steven J. M. Jones,et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.
[27] M. Edgren,et al. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo , 2009, International journal of cancer.
[28] A. Schönthal,et al. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy , 2007, British Journal of Cancer.
[29] B. Clausen,et al. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. , 2009, Cancer research.
[30] Amir Abdollahi,et al. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[31] K. McCarten,et al. Antitumor Activity of Nifurtimox Observed in a Patient With Neuroblastoma , 2006, Journal of pediatric hematology/oncology.
[32] Y. Shaked,et al. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. , 2010, Biochimica et biophysica acta.
[33] J Folkman,et al. Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.
[34] J. Blay,et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. , 2010, The Lancet. Oncology.
[35] Amanda J. Thomas,et al. A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.
[36] Patrick Lutz,et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[38] T. Crook,et al. Why does cytotoxic chemotherapy cure only some cancers? , 2009, Nature Clinical Practice Oncology.
[39] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[40] S. Libutti,et al. The tumour microenvironment: a novel target for cancer therapy. , 2009, Oral diseases.
[41] G. Schmid‐Bindert. Maintenance therapy in non-small-cell lung cancer. , 2011, Translational lung cancer research.
[42] Robert J. Gillies,et al. A microenvironmental model of carcinogenesis , 2008, Nature Reviews Cancer.
[43] S. Eccles,et al. Tumour-microenvironmental interactions: paths to progression and targets for treatment. , 2010, Seminars in cancer biology.
[44] J. Štěrba,et al. Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Single-Center Pilot Study , 2006, Oncology Research and Treatment.
[45] G. Gasparini,et al. Metronomic scheduling: the future of chemotherapy? , 2001, The Lancet. Oncology.
[46] Sui Huang,et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.
[47] T. Ashikaga,et al. A Phase 1 Study of Nifurtimox in Patients With Relapsed/Refractory Neuroblastoma , 2011, Journal of pediatric hematology/oncology.
[48] F. Ghiringhelli,et al. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model , 2009, Cancer Immunology, Immunotherapy.
[49] M. Ashraf,et al. Paclitaxel and immune system. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[50] G. Klement,et al. Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? , 2011, Journal of pediatric hematology/oncology.
[51] B. Chauffert,et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.
[52] A. Shaikh,et al. Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report , 2010, Journal of medical case reports.
[53] T. Mok,et al. Maintenance therapy in nonsmall‐cell lung cancer , 2009, Cancer.
[54] Peter Bohlen,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .
[55] Delong Liu,et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents , 2010, Journal of hematology & oncology.
[56] K. Jauch,et al. Cancer stem cells: how can we target them? , 2008, Current medicinal chemistry.
[57] A. Sica,et al. Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.
[58] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[59] M. Bosenberg,et al. Nifurtimox Induces Apoptosis of Neuroblastoma Cells In Vitro and In Vivo , 2009, Journal of pediatric hematology/oncology.